Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 643981, 8 pages
http://dx.doi.org/10.1155/2014/643981
Research Article

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction

1Department of Cardiology, Barts Health NHS Trust, London E2 9JX, UK
2Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
3NIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London E2 9JX, UK

Received 6 February 2014; Accepted 17 April 2014; Published 8 May 2014

Academic Editor: Satoaki Matoba

Copyright © 2014 J. P. Howard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Mehta, C. P. Cannon, K. A. A. Fox et al., “Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials,” Journal of the American Medical Association, vol. 293, no. 23, pp. 2908–2917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Braunwald, E. M. Antman, J. W. Beasley et al., “ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),” Journal of the American College of Cardiology, vol. 36, no. 3, pp. 970–1062, 2000. View at Google Scholar
  3. C. W. Hamm, J.-P. Bassand, S. Agewall et al., “ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC),” European heart journal, vol. 32, no. 23, pp. 2999–3054, 2011. View at Google Scholar · View at Scopus
  4. M. Roffi, D. P. Chew, D. Mukherjee et al., “Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy,” European Heart Journal, vol. 23, no. 18, pp. 1441–1448, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. “Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,” The New England Journal of Medicine, vol. 339, no. 7, pp. 436–443, 1998. View at Publisher · View at Google Scholar
  6. P. Théroux, “Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators,” The New England Journal of Medicine, vol. 338, no. 21, pp. 1488–1497, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kastrati, J. Mehilli, F.-J. Neumann et al., “Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1531–1538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Ndrepepa, A. Kastrati, J. Mehilli et al., “One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial,” European Heart Journal, vol. 29, no. 4, pp. 455–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. G. W. Stone, M. E. Bertrand, J. W. Moses et al., “Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial,” Journal of the American Medical Association, vol. 297, no. 6, pp. 591–602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. L. Brown, “Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment,” Heart, vol. 89, no. 5, pp. 535–537, 2003. View at Google Scholar · View at Scopus
  11. P. F. Ludman, “British Cardiovascular Intervention Society Registry for audit and quality assessment of percutaneous coronary interventions in the United Kingdom,” Heart, vol. 97, no. 16, pp. 1293–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Rosenbaum and D. B. Rubin, “The central role of the propensity score in observational studies for causal effects,” Biometrika, vol. 70, no. 1, pp. 41–55, 1983. View at Publisher · View at Google Scholar · View at Scopus
  13. P. R. Rosenbaum and D. B. Rubin, “Reducing bias in observational studies using subclassification on the propensity score,” Journal of the American Statistical Association, vol. 79, no. 387, pp. 516–524, 1984. View at Publisher · View at Google Scholar
  14. H. White, “A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators,” The New England Journal of Medicine, vol. 338, no. 21, pp. 1498–1505, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Moliterno, “International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network,” Circulation, vol. 97, no. 24, pp. 2386–2395, 1998. View at Google Scholar · View at Scopus
  16. R. A. Harrington, “Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes,” Circulation, vol. 105, no. 3, pp. 316–321, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Simoons, “Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial,” The Lancet, vol. 357, no. 9272, pp. 1915–1924, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Lenderink, E. Boersma, W. Ruzyllo et al., “Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS,” The American Heart Journal, vol. 147, no. 5, pp. 865–873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. M. El-Omar, G. Dangas, and G. W. Stone, “A comparison of tirofiban and abciximab in patients undergoing coronary stent implantation: rationale, design, and results of the TARGET trial,” Current Interventional Cardiology Reports, vol. 3, no. 4, pp. 336–345, 2001. View at Google Scholar
  20. G. De Luca, G. Ucci, E. Cassetti, and P. Marino, “Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis,” Journal of the American College of Cardiology, vol. 53, no. 18, pp. 1668–1673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi et al., “Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials,” European Heart Journal, vol. 31, no. 1, pp. 35–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Seghieri, S. Mimmi, J. Lenzi, and M. P. Fantini, “30-day in-hospital mortality after acute myocardial infarction in Tuscany (Italy): an observational study using hospital discharge data,” BMC Medical Research Methodology, vol. 12, article 170, 2012. View at Publisher · View at Google Scholar